ProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
ProKidney Corp. (Nasdaq: PROK), a leading late clinical-stage biotech company focused on developing a first-in-class cell therapy for chronic kidney disease (CKD), has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The event will take place in New York, NY from September 4-6, 2024.
Key details:
- Date: Thursday, September 5, 2024
- Time: 7:00 a.m. ET
- Format: Fireside Chat
A live webcast will be available through the company's website, with a 90-day replay option after the event. ProKidney's management team will also host one-on-one meetings with interested investors during the conference.
ProKidney Corp. (Nasdaq: PROK), una delle principali aziende biotecnologiche in fase clinica avanzata, focalizzata nello sviluppo di una terapia cellulare innovativa per la malattia renale cronica (CKD), ha annunciato la sua partecipazione alla 22ª Conferenza annuale globale sulla salute di Morgan Stanley. L'evento si svolgerà a New York, NY, dal 4 al 6 settembre 2024.
Dettagli chiave:
- Data: Giovedì, 5 settembre 2024
- Ora: 7:00 a.m. ET
- Formato: Conversazione informale
Un webcast in diretta sarà disponibile attraverso il sito web dell'azienda, con un'opzione di replay per 90 giorni dopo l'evento. Il team dirigente di ProKidney organizzerà inoltre incontri one-to-one con gli investitori interessati durante la conferenza.
ProKidney Corp. (Nasdaq: PROK), una destacada empresa de biotecnología en etapa clínica avanzada, centrada en el desarrollo de una terapia celular de primera clase para la enfermedad renal crónica (ERC), ha anunciado su participación en la 22ª Conferencia Global Anual de Salud de Morgan Stanley. El evento se llevará a cabo en Nueva York, NY, del 4 al 6 de septiembre de 2024.
Detalles clave:
- Fecha: Jueves, 5 de septiembre de 2024
- Hora: 7:00 a.m. ET
- Formato: Conversación junto a la chimenea
Se dispondrá de una transmisión en vivo a través del sitio web de la empresa, con una opción de repetición de 90 días después del evento. El equipo directivo de ProKidney también organizará reuniones individuales con inversores interesados durante la conferencia.
ProKidney Corp. (Nasdaq: PROK)는 만성 신장 질환(CKD)을 위한 최초의 세포 치료법 개발에 주력하는 주요 후기 임상 단계 생명공학 회사로, 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 4일부터 6일까지 뉴욕에서 개최됩니다.
주요 세부 사항:
- 날짜: 2024년 9월 5일 목요일
- 시간: 오전 7시 ET
- 형식: 화기 애애한 대화
회사의 웹사이트를 통해 생중계가 제공되며, 행사 후 90일간 다시 볼 수 있는 옵션이 있습니다. ProKidney의 경영진은 또한 컨퍼런스 기간 동안 관심 있는 투자자들과의 일대일 회의를 주최할 예정입니다.
ProKidney Corp. (Nasdaq: PROK), une entreprise biopharmaceutique de premier plan en phase clinique avancée, se concentrant sur le développement d'une thérapie cellulaire de première classe pour la maladie rénale chronique (MRC), a annoncé sa participation à la 22ème Conférence mondiale annuelle sur la santé de Morgan Stanley. L'événement se déroulera à New York, NY, du 4 au 6 septembre 2024.
Détails clés :
- Date : Jeudi 5 septembre 2024
- Heure : 7 h 00 ET
- Format : Conversation informelle
Une webdiffusion en direct sera disponible sur le site internet de l'entreprise, avec une option de rediffusion de 90 jours après l'événement. L'équipe de direction de ProKidney organisera également des réunions en tête-à-tête avec des investisseurs intéressés pendant la conférence.
ProKidney Corp. (Nasdaq: PROK), ein führendes Biotechnologie-Unternehmen in der späten klinischen Phase, das sich auf die Entwicklung einer ersten Zelltherapie der Klasse für chronische Nierenerkrankungen (CKD) konzentriert, hat seine Teilnahme an der 22. Morgan Stanley Global Healthcare Conference bekannt gegeben. Die Veranstaltung findet vom 4. bis 6. September 2024 in New York, NY, statt.
Wichtige Einzelheiten:
- Datum: Donnerstag, 5. September 2024
- Uhrzeit: 7:00 Uhr ET
- Format: Fireside Chat
Ein Live-Stream wird über die Unternehmenswebsite verfügbar sein, mit einer 90-tägigen Wiederholungsoption nach der Veranstaltung. Das Management-Team von ProKidney wird während der Konferenz auch persönliche Meetings mit interessierten Investoren organisieren.
- None.
- None.
WINSTON-SALEM, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney”), a leading late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that senior members of the management team will be participating in the Morgan Stanley 22nd Annual Global Healthcare Conference, being held in New York, NY on September 4-6, 2024.
| Morgan Stanley 22nd Annual Global Healthcare Conference | |
| Date: | Thursday, September 5, 2024 |
| Time: | 7:00 a.m. ET |
| Format: | Fireside Chat |
| Webcast Link: | https://cc.webcasts.com/morg007/090424a_js/?entity=120_8TXT47O |
The live webcast will also be accessible through the “Events” section of the Investor Relations tab within ProKidney’s website at www.prokidney.com. Following the completion of the fireside chat, a replay of the webcast will be available for 90 days.
The ProKidney management team will also host one-on-one meetings during this event. Interested investors should contact their Morgan Stanley representative to schedule meetings.
About ProKidney Corp.
ProKidney, a pioneer in the treatment of chronic kidney disease through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-of-its-kind, patented, proprietary autologous cellular therapy being evaluated to potentially preserve kidney function in patients with diabetes and advanced CKD. Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program.
Investor Contacts:
ProKidney
Ethan Holdaway
Ethan.Holdaway@prokidney.com
LifeSci Advisors, LLC
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
When is ProKidney (PROK) participating in the Morgan Stanley Healthcare Conference?
What type of presentation will ProKidney (PROK) give at the Morgan Stanley conference?
Where can investors access the webcast of ProKidney's (PROK) presentation?
How long will the replay of ProKidney's (PROK) presentation be available?
What is ProKidney's (PROK) main focus in biotechnology?
